Executive Summary
The India Healthcare Policy stream contains three filings, all from hospital operators (Yatharth Hospital and Global Health/Medanta); the Yatharth Q2 FY27 market notice and investor presentation describe the same results and Advent transaction and are treated as one underlying event.
Across the in-scope names, top-line momentum is strong: Yatharth revenue rose 52% YoY to Rs 4,314 mn in Q2 FY27 (+10% QoQ) and Global Health standalone revenue rose ~30.4% YoY to Rs 12,081 mn. Profitability growth is more uneven: Yatharth EBITDA grew 50% YoY but margin contracted 42 bps to 23.6% (adjusted ~28%), and PAT (+17% YoY) lagged revenue due to depreciation from new capacity, while Medanta PAT rose ~29% but finance costs more than doubled and depreciation rose ~50%. The dominant sector theme is capacity-led expansion, with new hospitals contributing 28% of Yatharth's Q2 revenue (vs 11% a year earlier) and Medanta approving a Rs 997 crore 500-bed Ghaziabad project. Capital is flowing in as well, with Advent's Rs 3,150 crore primary infusion into Yatharth for ~24.9%, while Medanta's operating cash flow and cash balance strengthened materially. Investors should weigh these growth and funding tailwinds against near-term margin dilution from ramp-up hospitals and rising debt-related costs.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior India Healthcare Pharma Policy Regulatory Filings digest from October 27, 2026.
Investment Signals (10)
- Yatharth Hospital ↓ (BULLISH)▲
Q2 FY27 revenue Rs 4,314 mn, +52% YoY and +10% QoQ; H1 FY27 revenue Rs 8,241 mn (+52% YoY) with PAT Rs 939 mn (+33% YoY)
- Yatharth Hospital ↓ (BULLISH)▲
ARPOB rose 11% YoY to Rs 35,948 in Q2 FY27, indicating pricing/case-mix support alongside volume growth
- Yatharth Hospital ↓ (BULLISH)▲
Advent International definitive agreement for Rs 3,150 crore primary capital (~24.9% on full conversion), with promoter family retaining ~42% as largest shareholder, subject to regulatory approvals
- Yatharth Hospital ↓ (BEARISH)▲
EBITDA margin contracted 42 bps YoY to 23.6% (adjusted ~28% excluding New Delhi and Faridabad Sector-20 ramp-up), so reported margin trend is a watch item
- Yatharth Hospital ↓ (BULLISH)▲
Faridabad Sector-20 and Agra turned EBITDA positive in H1 FY27, with New Delhi guided to breakeven in H2 FY27, a concrete ramp-up catalyst
- Yatharth Hospital ↓ (BEARISH)▲
Occupancy eased to 70% in H1 FY27 from 72% in Q2 alone, while new hospitals rose to 28% of revenue mix (vs 11% in Q2 FY26), signalling mix-driven utilisation pressure
- Global Health (Medanta) (BULLISH)▲
Q2 FY27 standalone revenue Rs 12,081 mn, +30.4% YoY; PAT Rs 1,813 mn, +29.3% YoY; basic EPS Rs 6.75 vs Rs 5.22
- Global Health (Medanta) (BULLISH)▲
H1 FY27 operating cash flow rose to Rs 4,260 mn from Rs 2,614 mn (+63%), and cash & equivalents reached Rs 2,045 mn at 30-Sep-2026 vs Rs 959 mn at 31-Mar-2026
- Global Health (Medanta) (BULLISH)▲
Board approved Rs 997 crore budget for a 500-bed hospital on 10,560 sq m at Siddharth Vihar Yojna, Ghaziabad, allotted by UPAVP, signalling a multi-year expansion pipeline
- Global Health (Medanta) (BEARISH)▲
Finance costs more than doubled to Rs 171 mn (from Rs 89 mn) and depreciation rose to Rs 562 mn (from Rs 374 mn), eroding some operating leverage
Risk Flags (7)
- Yatharth Hospital/Margin Dilution↓ [HIGH RISK]▼
Reported EBITDA margin fell 42 bps YoY to 23.6% and PAT growth (+17%) trailed revenue growth (+52%) as depreciation from new capacity rose
- Yatharth Hospital/Ramp-up Execution↓ [MEDIUM RISK]▼
New hospitals now 28% of revenue and occupancy slipped to 70% in H1 FY27; delays in New Delhi breakeven (guided H2 FY27) would pressure reported margins further
- Yatharth Hospital/Deal Execution↓ [MEDIUM RISK]▼
Advent transaction remains subject to regulatory approvals; any delay or change in terms would affect the Rs 3,150 crore funding and balance-sheet plans
- Global Health (Medanta)/Financing Cost [MEDIUM RISK]▼
Finance costs more than doubled YoY to Rs 171 mn, raising sensitivity to interest rates as the company funds its Ghaziabad 500-bed project
- Global Health (Medanta)/Earnings Quality [MEDIUM RISK]▼
Prior-year quarter included a Rs 356 mn exceptional item, so the reported +29% PAT growth flatters underlying momentum; investors should check recurring earnings
- Global Health (Medanta)/Capex Burden [MEDIUM RISK]▼
Rs 997 crore project budget (incl. land) for a single greenfield hospital adds meaningful capital commitment and depreciation load ahead of revenue ramp
- Sector/Capital Intensity [MEDIUM RISK]▼
Both operators are scaling capex faster than mature-hospital margins, so depreciation and interest headwinds may outpace revenue growth if occupancy stalls
Opportunities (7)
- Yatharth Hospital/Advent Catalyst↓ (OPPORTUNITY)◆
Rs 3,150 crore primary infusion from Advent International at a strategic-investor valuation, with approval-driven closing as a near-term event to monitor
- Yatharth Hospital/Margin Recovery↓ (OPPORTUNITY)◆
Adjusted EBITDA margin ~28% versus reported 23.6% implies meaningful upside as Faridabad Sector-20, Agra and New Delhi mature, with New Delhi breakeven targeted in H2 FY27
- Yatharth Hospital/Operating Leverage↓ (OPPORTUNITY)◆
Revenue up 52% YoY and EBITDA up 50% YoY in Q2 FY27 shows scale benefits as new hospitals ramp; occupancy recovery from 70% would lift fixed-cost absorption
- Global Health (Medanta)/Earnings Momentum (OPPORTUNITY)◆
Revenue +30% and PAT +29% YoY with EPS up ~29% (Rs 6.75 vs Rs 5.22) combined with the cash build to Rs 2,045 mn gives room for continued expansion funding
- Global Health (Medanta)/Expansion Pipeline (OPPORTUNITY)◆
The Ghaziabad 500-bed project (Rs 997 crore) extends Medanta's NCR footprint and, if executed, adds a major capacity block to lift revenue in future periods
- Global Health (Medanta)/Cash Generation (OPPORTUNITY)◆
H1 FY27 operating cash flow of Rs 4,260 mn (+63% YoY) supports self-funded capex, reducing reliance on external debt and mitigating the finance-cost trend
- Sector/Private Hospital Demand (OPPORTUNITY)◆
Both companies reporting 30%+ top-line growth on capacity additions indicates sustained demand for tertiary private care in North India
Sector Themes (5)
- Capacity-Led Growth in Private Hospitals (THEME)◆
Both in-scope operators are growing revenue 30-50% YoY on new hospital additions (Yatharth new hospitals 28% of revenue vs 11% a year earlier), indicating expansion-driven rather than same-store growth
- Ramp-up Margin Dilution (THEME)◆
Yatharth's reported margin (23.6%) sits ~440 bps below its adjusted ~28%, showing newer hospitals weigh on reported profitability during the 12-24 month maturation window
- Depreciation and Finance Cost Headwinds (THEME)◆
Medanta's depreciation rose ~50% and finance costs more than doubled YoY, and Yatharth's PAT growth lagged revenue due to depreciation, pointing to rising fixed-cost burden across the sub-sector
- Capital Access via Strategic and Operating Cash Flows (THEME)◆
Yatharth is bringing in strategic PE capital (Advent, Rs 3,150 crore) while Medanta self-funds through operating cash flow (H1 FY27 Rs 4,260 mn), showing two distinct funding models for expansion
- Greenfield NCR Expansion (THEME)◆
Medanta's Ghaziabad 500-bed project and Yatharth's Faridabad/New Delhi/Agra ramp-ups highlight continued concentration of hospital capacity in the Delhi-NCR belt
Watch List (7)
-
Regulatory approvals and closing timing for the Rs 3,150 crore primary investment (~24.9%); check for timeline updates in the next filings [Date TBD]
-
Management guided New Delhi to EBITDA breakeven in H2 FY27; confirm in Q3 FY27 results and track the adjusted vs reported margin gap [Q3 FY27 results, date TBD]
-
H1 occupancy of 70% vs 72% in Q2 alone; watch whether utilisation recovers as new hospitals mature [Q3 FY27 results, date TBD]
- Global Health (Medanta)/Finance Cost Trajectory👁
Finance costs rose to Rs 171 mn (from Rs 89 mn); monitor borrowing levels and rate sensitivity as the Ghaziabad project progresses [Q3 FY27 results, date TBD]
- Global Health (Medanta)/Ghaziabad Project Execution👁
Track land allotment formalities, construction milestones and funding structure for the Rs 997 crore 500-bed hospital at Siddharth Vihar Yojna [Next board update, date TBD]
- Global Health (Medanta)/Recurring Earnings Quality👁
Confirm the underlying PAT trend excluding prior-year exceptional items in the next quarterly disclosure [Q3 FY27 results, date TBD]
- Sector/Regulatory Environment👁
Monitor Ayushman Bharat and NHA/PM-JAY reimbursement developments, which affect hospital case-mix and occupancy for both operators [Ongoing]
Filing Analyses
(3)
03-11-2026
Yatharth Hospital reported record Q2 FY27 revenue of Rs 4,314 mn, up 52% YoY and 10% QoQ, with EBITDA up 50% YoY to Rs 1,020 mn and PAT up 17% YoY to Rs 485 mn. However, EBITDA margin contracted 42 bps YoY to 23.6% (adjusted 28%), and PAT growth of 17% lagged revenue growth due to higher depreciation from capacity additions. The company also announced a definitive agreement with Advent International for a primary capital investment of Rs 3,150 crore, with Advent to hold ~24.9% on full conversion.
- · Adjusted EBITDA margin stood at 28% in Q2 FY27, excluding impact of New Delhi and Faridabad Sector-20
- · New hospitals contributed 28% to Group revenue in Q2 FY27 vs 11% in Q2 FY26
- · Faridabad Sector-20 and Agra turned EBITDA positive in H1 FY27; New Delhi expected to breakeven in H2
- · Premium NCR hospitals of Noida Extension and New Delhi approached ~Rs 50k ARPOB mark
- · Quarterly revenue and profits have nearly tripled since listing in 2023
- · Earnings conference call scheduled November 4, 2026 at 11:00 am IST
- · Advent investment described as one of the largest primary fund infusions by a private equity in India's hospital sector
- · Promoter family remains the largest shareholder post Advent conversion
03-11-2026
Yatharth Hospital & Trauma Care Services Limited filed its Q2 & H1 FY27 investor presentation, reporting Q2 FY27 revenue of Rs 4,314 mn (+52% YoY, +10% QoQ) and EBITDA of Rs 1,020 mn (+50% YoY, +11% QoQ) at a 23.6% margin (adjusted ~28%). H1 FY27 revenue reached Rs 8,241 mn (+52% YoY) with EBITDA of Rs 1,937 mn (+44% YoY) and PAT of Rs 939 mn (+33% YoY), while occupancy was 70% in H1 versus 72% in Q2 and ARPOB rose 11% YoY to Rs 35,948 in Q2. The company also disclosed a strategic partnership with Advent involving a Rs 3,150 crore primary capital infusion for a 24.9% stake, with the promoter family retaining ~42% as largest shareholder, subject to regulatory approvals.
- · Adjusted EBITDA margin ~28% excludes ramp-up impact from newer hospitals Model Town and Faridabad Sector-20
- · New hospitals contributed 28% of revenue mix in Q2 FY27 versus 11% in Q2 FY26
- · H1 FY27 ALOS was 3.51 days; Q2 FY27 ALOS was 3.33 days
- · Advent has over US $109 Bn assets under management
- · Promoter family to remain largest shareholder at ~42% post dilution; Advent deal awaiting regulatory approvals
- · H1 FY27 cash conversion ratio 57% and total cash RoCE 16%
- · Net debt stood at Rs 392 mn
03-11-2026
Global Health Limited (Medanta) reported Q2 FY27 standalone revenue from operations of ₹12,080.94 million, up ~30.4% YoY from ₹9,264.28 million, with profit after tax rising ~29.3% to ₹1,812.59 million versus ₹1,401.99 million. However, finance costs more than doubled to ₹170.65 million from ₹88.83 million and depreciation rose to ₹561.51 million from ₹374.28 million, while the prior-year quarter benefited from a ₹355.77 million exceptional item. The Board also approved a ₹997 Crore project budget (including land cost) for a 500-bedded hospital on 10,560.36 sq. meters at Siddharth Vihar Yojna, Ghaziabad, allotted by UPAVP, and auditors issued an unmodified limited review opinion.
- · Basic EPS for Q2 FY27 was ₹6.75 versus ₹5.22 in Q2 FY26; H1 FY27 basic EPS ₹11.85 versus ₹10.87
- · H1 FY27 net cash from operating activities rose to ₹4,259.51 million from ₹2,614.38 million
- · Cash and cash equivalents stood at ₹2,045.27 million as of September 30, 2026 versus ₹959.08 million at March 31, 2026
- · Total borrowings (non-current) increased to ₹5,175.68 million from ₹4,492.02 million as of March 31, 2026
- · Trading window to reopen 48 hours after results declaration
- · Board meeting commenced at 02:00 P.M. and concluded at 03:45 P.M.
- · Auditors issued unmodified limited review opinion on standalone and consolidated results
Get daily alerts with 10 investment signals, 7 risk alerts, 7 opportunities and full AI analysis of all 3 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India Healthcare Pharma Policy Regulatory Filings
October 23, 2026
India Healthcare Pharma Policy Regulatory Filings — October 23, 2026
October 15, 2026
India Healthcare Pharma Policy Regulatory Filings — October 15, 2026
October 03, 2026
India Healthcare Pharma Policy Regulatory Filings — October 03, 2026
September 23, 2026
India Healthcare Pharma Policy Regulatory Filings — September 23, 2026
🇮🇳 More from India
View all →October 27, 2026
India Upcoming Corporate Actions BSE NSE — October 27, 2026
India Upcoming Corporate Actions BSE NSE
October 27, 2026
India Pre-Market Regulatory Roundup — October 27, 2026
India Pre-Market Regulatory Roundup
October 27, 2026
India Quarterly Results BSE NSE Announcements — October 27, 2026
India Quarterly Results BSE NSE Announcements
October 27, 2026
BSE Bankex Banking Sector Regulatory Filings — October 27, 2026
BSE Bankex Banking Sector Regulatory Filings